![Michael J. Brennan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael J. Brennan
Directeur/Membre du Conseil chez
Cloud Pharmaceuticals, Inc.
Profil
Dr. Michael J.
Brennan is a Managing Director at Pearl Street Venture Funds.
Prior to Pearl Street,he was a General Partner at Oxford Bioscience Partners.
Prior to that, he was President and Chief Executive Officer of Gene Logic.
During Dr. Brennan’s time at Gene Logic, he built the company from a start-up to a public company that achieved a market capitalization of over $5 billion.
He raised three rounds of venture capital and led Gene Logic to an IPO in November, 1997 and a large secondary public offering in January, 2000.
Dr. Brennan’s previous experience includes six years in the biopharmaceutical industry, where he has served as Vice President, Business Development for Boehringer Mannheim Therapeutics.
Dr. Brennan received a B.S.
in Biochemistry, a Ph.D.
in neurobiology and a M.D.
from the University of Witwatersrand, Johannesburg, South Africa.
Postes actifs de Michael J. Brennan
| Sociétés | Poste | Début |
|---|---|---|
Pearl Street Venture Funds
 Pearl Street Venture Funds Investment ManagersFinance Pearl Street Ventures Funds invests in companies located in United States, primarily in Indiana. The firm targets companies operating across a broad range of sectors. It provide financing for early stage capital requirements. | Private Equity Investor | - |
Cloud Pharmaceuticals, Inc.
 Cloud Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Directeur/Membre du Conseil | - |
Anciens postes connus de Michael J. Brennan
| Sociétés | Poste | Fin |
|---|---|---|
Ore Pharmaceuticals, Inc.
 Ore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Directeur/Membre du Conseil | 27/04/2009 |
Gene Logic, Inc.
 Gene Logic, Inc. BiotechnologyHealth Technology Develops and discovers pharmaceutical | Directeur/Membre du Conseil | 03/01/2008 |
Coastview Capital LLC
 Coastview Capital LLC Investment ManagersFinance Coastview Capital seeks to identify promising new drug candidates and bottlenecks in the drug discovery process. They look for companies that are working to create new product opportunities and new technologies to improve drug discovery and drug discovery processes. When evaluating a company they look for the following components: innovative, breakthrough science, a top management team, able to build the right mix of science and business capabilities, products and technology platforms that address real pharmaceutical industry needs, market and commercial potential and a strong current or potential intellectual property position. Coastview invests across all stages of development, although their current focus is primarily on later-stage companies. The firm considers investments in all geographical areas, depending on their investment criteria being met and the involvement of other key investors. Initial investments range from $1 million to $5 million and up to a total of $10 million over the life of the company. Their preferred regions for investments are Southern California, Boston, the San Francisco Bay area and the greater Washington DC area. | Private Equity Investor | 30/06/2006 |
| TAURIGA SCIENCES, INC. | Directeur/Membre du Conseil | - |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Corporate Officer/Principal | - |
Formation de Michael J. Brennan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
44
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
Casella Waste Systems, Inc.
 Casella Waste Systems, Inc. Environmental ServicesIndustrial Services Provides solid waste collection and waste management services | Industrial Services |
Gene Logic, Inc.
Gene Logic, Inc. BiotechnologyHealth Technology Develops and discovers pharmaceutical | Health Technology |
Cloud Pharmaceuticals, Inc.
Cloud Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Coastview Capital LLC
Coastview Capital LLC Investment ManagersFinance Coastview Capital seeks to identify promising new drug candidates and bottlenecks in the drug discovery process. They look for companies that are working to create new product opportunities and new technologies to improve drug discovery and drug discovery processes. When evaluating a company they look for the following components: innovative, breakthrough science, a top management team, able to build the right mix of science and business capabilities, products and technology platforms that address real pharmaceutical industry needs, market and commercial potential and a strong current or potential intellectual property position. Coastview invests across all stages of development, although their current focus is primarily on later-stage companies. The firm considers investments in all geographical areas, depending on their investment criteria being met and the involvement of other key investors. Initial investments range from $1 million to $5 million and up to a total of $10 million over the life of the company. Their preferred regions for investments are Southern California, Boston, the San Francisco Bay area and the greater Washington DC area. | Finance |
University of the Witwatersrand
 University of the Witwatersrand Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pearl Street Venture Funds
Pearl Street Venture Funds Investment ManagersFinance Pearl Street Ventures Funds invests in companies located in United States, primarily in Indiana. The firm targets companies operating across a broad range of sectors. It provide financing for early stage capital requirements. | Finance |
Ore Pharmaceuticals, Inc.
Ore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Tauriga Sciences, Inc.
 Tauriga Sciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
